COVID-19 has raised the importance of research into fighting infectious diseases that threaten populations.
The World Health Organization calls antimicrobial resistance, resulting from the overuse of antibiotics or other drugs, one of the top 10 public health threats. In fact, the next global pandemic could be another novel respiratory pathogen of zoonotic origins or a multidrug resistant strain of a previously eradicated pathogen.
In this whitepaper we provide a framework for understanding the antimicrobial crisis and the role healthcare and biopharma industries have to play in mitigating the impact of future pandemics.Read the whitepaper
HIV is highly heterogeneous, creating barriers to diagnosing and treating the disease. Moreover, the HIV epidemic varies by region and country, necessitating different clinical research strategies across geographies. In this whitepaper, we discuss opportunities for addressing these challenges, best practices for managing infectious disease clinical trials and recent developments in HIV treatment.Read the whitepaper
Vaccine trials for respiratory viruses, even in the best of circumstances, present a number of operational challenges for researchers, many of which are exacerbated in the face of a pandemic created by a novel virus. We focus on the corresponding success factors that can keep pandemic respiratory vaccine trials running at optimal speed and efficiency.Read the whitepaper
Before antiretroviral treatment availability, life expectancy for a person living with HIV was reduced by approximately 12.5 years. Now, this same individual will have near-normal life expectancy.Download the infographic
The employment of antimicrobials to fight previously devastating microbial diseases, such as tuberculosis, meningitis and pneumonia has been a transformative medical achievement.
The UNICEF Corporate Vaccine Alliance supports UNICEF’s goal to deliver over two billion COVID-19 vaccines by the end of 2021.
Discover how in-home services and a global development strategy can help us get closer to more effective treatments.
How one virus accelerated vaccine research, spurring innovation and hope for a cure in another.
The success factors that can keep pandemic respiratory vaccine trials running at optimal speed and efficiency.
Is this a health risk that can be dealt with sooner than later?
A look at the potential impact of Coronavirus.
How COVID-19 altered clinical trials forever and what’s next.
Need for rapid diagnostic testing to identify and track people infected by or exposed to coronavirus.
Shelley McLendon outlines what lessons must be learned to prevent future other emerging infectious diseases developing on a similar scale.
Shelley Mclendon, Vice President, Vaccine and Infectious Disease, offers her insights on the necessary actions to combat the threat of AMR.
Shelley Mclendon discusses the use of novel diagnostics to help monitor for AMR outbreaks and reduce the overuse and misuse of antimicrobials.
Caroline Forkin, Vice President for Clinical Research Services, offers her insights on the various actions that should be taken to improve AMR planning.
Nicole A. Cowan explores how glycomics is joining genomics and proteomics in the study of disease mechanisms and the development of novel therapeutics.
Dr. Johan Du Toit, Executive Director, Internal Medicine, considers strategies from COVID era clinical trials for addressing the public health crisis of antimicrobial resistance.
In this report, Dr Steve Cutler describes ICON’s efforts to combat the COVID-19 pandemic and how the crisis has pushed new digital technologies forward (page 14).
In this article, CFO Brendan Brennan discusses the responsibility of CROs in the fight against COVID-19, particularly by helping the most vulnerable populations gain access to vaccines and treatments.
In this radio interview, CFO Brendan Brennan briefly discusses the disparity of vaccine rollouts of developed countries compared to less economically developed countries, and the role of ICON as a key partner in developing the Pfizer COVID-19 vaccine.
Shelley McLendon considers the knock-on effect of COVID-19 for other infectious diseases, and what we can do to speed up development of future vaccines.
Dr. Caroline Forkin, VP Clinical Research Services, considers the best approach to address antimicrobial resistance.
Nuala Murphy, President Global Specialty Solutions, contributes to the Bottom Line BBC4 podcast about the impact of the COVID-19 vaccine on the clinical trial process and whether these changes could work for other drugs.
An article featuring commentary from Dr. Nuala Murphy on ICON’s learnings from conducting the Pfizer/BioNTech trial.
An interview in which Steve Cutler gives a short overview of ICON and describes the company’s role in the Pfizer/BioNTech trial, explaining how the FDA played a critical role in expediting regulatory approvals.
Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases at ICON, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership.
ICON CEO Steve Cutler, discusses running the Pfizer / BioNTech vaccine trial, and how it proved the value of partnership, and the key role of technology.
Dr Nuala Murphy, President of Clinical Services, talks exclusively to Pharmafield about the Pfizer / BioNTech COVID-19 vaccine trial and the implications this has on the future of drug development.
Dr. Caroline Forkin discusses the current status of HIV treatments and potential for researchers to develop a vaccine.
Dr. Caroline Forkin and Shelley McLendon discuss a new decade of research and innovation on the horizon for HIV.
Running HIV trials requires new and creative approaches, to combat stigma and reflect the diverse cultural, lifestyle and biological circumstances.
COVID-19 vaccine trials.
Starting clinical trials in weeks, as opposed to months, should be possible post-pandemic. (PDF)
Irish clinical trials group Icon has revealed that it carried out the late-stage trial of the Pfizer-BioNTech coronavirus vaccine.
Dr. Murphy of ICON, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale.
An immediate by-product of the COVID-19 pandemic has been an increase in antimicrobialresistant infections, including Clostridioides difficile.
The global effort to create a vaccine on such short notice is unprecedented.
ICON mobilised its vaccine resources to address the COVID-19 global pandemic. (PDF)
Evidence and lessons for public health policies.
Recommendations for study planning, enrolment, surveillance and study closeout.
ICON’s extensive Infectious Disease expertise enables us to consistently select the best sites, expedite start-up timelines, and achieve enrolment targets for our clients. We apply proven strategies to clinical trials that minimise risk and generate high-quality, reliable data reducing the time and cost of bringing new therapies to market.Read more about ICON's services in infectious diseases and vaccines